Hyperprogression after immunotherapy in HNC: literature review and our experience

Nerina Denaro

Checkpoint inhibitors demonstrate salutary anticancer effects, including long-term remissions. PD-L1 expression/amplification, high mutational burden, and mismatch repair deficiency correlate with response. Champiat et al for the first time described a small subset of patients that could actually have tumor growth accelerated when given PD1/PDL1-targeting agents [1].

Hyperprogression may be defined as accelerated progression outpaces the expected rate of growth induced by the therapies.

Champiat suggests that a subset of patients with disease progression have a course that is more deleterious than they might have had with other therapies, or even in the absence of therapy.

Keywords: immunotherapy

Published on: Mar 15, 2018 Pages: 1-2

Full Text PDF Full Text HTML DOI: 10.17352/ijrro.000026
CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat